KNOCK OUT OF ??1,3-GALACTOSYLTRANSFERASE OR EXPRESSION OF??1,2-FUCOSYLTRANSFERASE FURTHER PROTECTS CD55- AND CD59-EXPRESSING MOUSE HEARTS IN AN EX VIVO MODEL OF XENOGRAFT REJECTION
- 1 June 1998
- journal article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 65 (12) , 1599-1604
- https://doi.org/10.1097/00007890-199806270-00010
Abstract
Organs from transgenic animals with high-level endothelial expression of the human complement regulatory factors CD55 and CD59 are significantly protected from human complement-mediated injury. Elimination or reduction of the major xenoepitope alphaGal, achieved by knocking out the alpha1,3-galactosyltransferase gene (Gal KO) or expressing human alpha1,2-fucosyltransferase (H transferase or HTF), also affords protection, although to a lesser degree. In this study, we examined whether the protection provided by strong CD55 and CD59 expression can be augmented by the Gal KO or HTF modifications. Hearts from four groups of mice (wild type, CD55/CD59, CD55/CD59/HTF, and CD55/CD59/Gal KO) were perfused ex vivo with 40% human plasma. Mean heart work for each group was compared over a 60-min period. Wild-type hearts ceased to function effectively within 15 min of plasma addition. CD55/CD59 hearts displayed prolonged survival and maintained approximately 10% maximum work at the end of perfusion. Introduction of Gal KO or HTF onto the CD55/CD59 background resulted in a further prolongation, with work maintained at 20-30% of the maximum level. We used an ex vivo model to demonstrate that eliminating alphaGal expression further prolongs the function of mouse hearts expressing high levels of CD55 and CD59. In addition, we showed that reducing alphaGal by expressing HTF is equally as effective in prolonging CD55/CD59 heart function as knocking out Gal transferase, thus providing a feasible strategy for translating these advances to the pig.Keywords
This publication has 33 references indexed in Scilit:
- HIGH-LEVEL ENDOTHELIAL EXPRESSION OF HUMAN CD59 PROLONGS HEART FUNCTION IN AN EX VIVO MODEL OF XENOGRAFT REJECTIONTransplantation, 1998
- CHANGES IN CELL SURFACE GLYCOSYLATION IN ??1,3-GALACTOSYLTRANSFERASE KNOCKOUT AND ??1,2-FUCOSYLTRANSFERASE TRANSGENIC MICETransplantation, 1997
- Transgenic expression of a CD46 (membrane cofactor protein) minigene: Studies of xenotransplantation and measles virus infectionEuropean Journal of Immunology, 1997
- The prospects for renal xenotransplantationNephrology, 1996
- TARGETING GENE EXPRESSION TO ENDOTHELIAL CELLS IN TRANSGENIC MICE USING THE HUMAN INTERCELLULAR ADHESION MOLECULE 2 PROMOTER1Transplantation, 1996
- A membrane cofactor protein transgenic mouse model for the study of discordant xenograft rejectionGenes to Cells, 1996
- EXPRESSION OF FUNCTIONAL DECAY-ACCELERATING FACTOR (CD55) IN TRANSGENIC MICE PROTECTS AGAINST HUMAN COMPLEMENT-MEDIATED ATTACK1Transplantation, 1996
- Reduction in Gal‐α1,3‐Gal epitope expression in transgenic mice expressing human H‐transferaseXenotransplantation, 1996
- Reduction of the major porcine xenoantigen Galoc(1,3)Gal by expression of α(1,2)fucosyltransferaseXenotransplantation, 1996
- Protection from complement‐mediated injury in livers and kidneys of transgenic mice expressing human complement regulatorsXenotransplantation, 1996